{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:18:12Z","timestamp":1787840292505,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Extranodal natural killer\/T-cell lymphoma, nasal type (ENKL), or nasal NK\/T-cell lymphoma is the most common cause of the syndrome known as \u201cfatal midline granuloma.\u201d<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>In this study, we aimed to analyze the treatment outcomes of extranodal natural killer (NK)\/T-cell lymphomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data of 39 patients from 15 centers were evaluated retrospectively. The characteristics that determine the risk status of the patients, in which treatments they received, and their responses were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Complete response was achieved in 21 patients (53.8%) who received first-line therapy. Median follow-up was 12.5 months (range, 1-60 months) and mortality was 56.4% in patients with highly advanced disease. Median overall survival was 16 (95% CI, 13.07-18.93) months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The prognosis of patients with ENKL has been improved with the use of anthracycline-free treatments, but mortality rates remain high in advanced patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_499_24","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T01:01:31Z","timestamp":1748998891000},"page":"602-607","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Extranodal Nasal-Type NK\/T-Cell Lymphoma Treatment: Analysis from a Multicenter Study"],"prefix":"10.4103","volume":"28","author":[{"given":"D","family":"Sahin","sequence":"first","affiliation":[{"name":"Department of Hematology, Etlik City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Soyer","sequence":"additional","affiliation":[{"name":"Ege University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Yeral","sequence":"additional","affiliation":[{"name":"Department of Hematology and Adult Bone Marrow Transplantation Centre, University of Baskent, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Namdaroglu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dokuz Eyl\u00fcl Univercity, \u0130zmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Hindilerden","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Aydogdu","sequence":"additional","affiliation":[{"name":"Celal Bayar University, Manisa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HBA","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Etlik City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Turgut","sequence":"additional","affiliation":[{"name":"Nam\u0131k Kemal University, Tekirdag, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Bilgir","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MS","family":"Dal","sequence":"additional","affiliation":[{"name":"Department of Hematology and Apheresis Unit, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gunes","sequence":"additional","affiliation":[{"name":"Ege University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MH","family":"Dogu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Istinye University, Liv Hospital Ulus, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Demircioglu","sequence":"additional","affiliation":[{"name":"Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tombak","sequence":"additional","affiliation":[{"name":"Mersin University, Mersin, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Vural","sequence":"additional","affiliation":[{"name":"Ege University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Gulturk","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Korkmaz","sequence":"additional","affiliation":[{"name":"Department of Hematology and Apheresis Unit, University of Health Sciences, Kayseri City Training and Research Hospital, Kayseri, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ulas","sequence":"additional","affiliation":[{"name":"Department of Hematology and Apheresis Unit, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Eser","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical Park Antalya Hospital, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Altuntas","sequence":"additional","affiliation":[{"name":"Department of Hematology and Apheresis Unit, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey"},{"name":"Department of Internal Medicine, Division of Hematology, Ankara Yildirim Beyazit University, School of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"R1-20260422","first-page":"146","article-title":"Extranodal NK\/T-cell lymphoma, nasal type (ENKL)","volume":"23","author":"Salcedo","year":"2019","journal-title":"Atlas Genet Cytogenet Oncol Haematol"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2141.2005.05694.x","article-title":"Selective apoptosis of natural killer-cell tumours by l-asparaginase","volume":"130","author":"Ando","year":"2005","journal-title":"Br J Haematol"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdn542","article-title":"L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature","volume":"20","author":"Jaccard","year":"2009","journal-title":"Ann Oncol"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02983387","article-title":"L-asparaginase-based regimen in the treatment of refractory midline nasal\/nasal-type T\/NK-cell lymphoma","volume":"78","author":"Yong","year":"2003","journal-title":"Int J Hematol"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/17474086.2016.1206465","article-title":"Diagnosis and management of extranodal NK\/T cell lymphoma nasal type","volume":"9","author":"Tse","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/sj.leu.2403955","article-title":"Natural killer-cell malignancies: Diagnosis and treatment","volume":"19","author":"Kwong","year":"2005","journal-title":"Leukemia"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cncr.30697","article-title":"The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States","volume":"123","author":"Vargo","year":"2017","journal-title":"Cancer"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: The NK-Cell tumor study group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: Analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clml.2018.04.009","article-title":"Natural killer\/T-cell neoplasms: Analysis of \u0131ncidence, patient characteristics, and survival outcomes in the United States","volume":"18","author":"Kommalapati","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: Analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-Cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08\u201301 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1200\/JCO.2016.68.1619","article-title":"Treatments and outcomes of patients with extranodal natural killer\/T-Cell lymphoma diagnosed between 2000 and 2013: A cooperative study in Japan","volume":"35","author":"Yamaguchi","year":"2017","journal-title":"J Clin Oncol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-16-0153","article-title":"DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: A randomized controlled, multicenter, open-label study in China","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6602502","article-title":"Nasal-type NK\/T cell lymphoma: Clinical features and treatment outcome","volume":"92","author":"Lee","year":"2005","journal-title":"Br J Cancer"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-014-2228-4","article-title":"Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III\/IV NK\/T cell-lymphoma, nasal type (NTCL)","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"issue":"15_suppl","key":"R20-20260422","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1200\/jco.2014.32.15_suppl.8552","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type\u2014a new staging system from CSWOG\u2014a multicenter study","volume":"32","author":"Lin","year":"2014","journal-title":"J Clin Oncol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"issue":"Suppl 5","key":"R22-20260422","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d\u2019Amore","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_499_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:19:37Z","timestamp":1787836777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_499_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_499_24","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-08-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}